Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Epi-Ret was a German medical technology company focused on the development of epiretinal prostheses to restore vision in patients with degenerative retinal diseases. The company's flagship product, the Epi-Ret 3, was a fully implantable, wireless retinal stimulator designed to bypass damaged photoreceptors and directly stimulate retinal ganglion cells. Developed through a multi-institutional consortium in Germany, the device aimed to provide functional vision to individuals blinded by conditions such as retinitis pigmentosa. The system was unique for its wireless design, which eliminated the need for trans-scleral cables, potentially reducing surgical complications. While the technology demonstrated technical feasibility in early clinical trials, the company is no longer active in the commercial market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Epi-Ret.